Wechselwirkungen von Adalimumab

The concomitant use of a TNF blocker and abatacept or anakinra was associated with a higher risk of serious infections in patients with rheumatoid arthritis (RA); therefore, the concomitant use of Adalimumab-fkjp and these biologic products is not recommended in the treatment of patients with RA [see Warnings and Precautions (5.7 , 5.11) and Drug Interactions… (Fachinformation zu Adalimumab, Warnhinweise und Vorsichtsmaßnahmen)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (Fachinformation zu Captopril, Warnhinweise)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Immunosuppressant/neoplastic: everolimus Co-administration of everolimus and PREZISTA/ritonavir is not recommended. irinotecan Discontinue PREZISTA/ritonavir at least 1 week prior to starting irinotecan therapy. (Fachinformation zu Darunavir, Arzneimittelwechselwirkungen)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Immunosuppressants Everolimus Sirolimus Temsirolimus (IV) Not recommended during and 2 weeks after TOLSURA treatment. (Fachinformation zu Itraconazol, Arzneimittelwechselwirkungen)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

…methylergonovine • HMG-CoA reductase inhibitors: lovastatin, simvastatin (these drugs can be temporarily discontinued to allow PAXLOVID use [see Table 2 , Drug Interactions (7.3) ] ) • Immunosuppressants: voclosporin • Microsomal triglyceride transfer protein inhibitor: lomitapide • Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists:… (Fachinformation zu Nirmatrelvir und Ritonavir, Gegenanzeigen)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Major Adverse Cardiovascular Events (MACE) Another JAK inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. (Fachinformation zu Ruxolitinib, Warnhinweise und Vorsichtsmaßnahmen)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (Fachinformation zu Adalimumab, Arzneimittelwechselwirkungen)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (Fachinformation zu Adalimumab, Arzneimittelwechselwirkungen)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Fachinformation zu Amlodipin, Arzneimittelwechselwirkungen)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Fachinformation zu Amlodipin und Atorvastatin, Arzneimittelwechselwirkungen)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Fachinformation zu Amlodipin und Olmesartan, Arzneimittelwechselwirkungen)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when coadministered. (Fachinformation zu Amlodipin und Valsartan, Arzneimittelwechselwirkungen)

Immunosuppressants: cyclosporine, sirolimus, tacrolimus ↑ immunosuppressants Therapeutic concentration monitoring is recommended for these immunosuppressants when coadministered with REYATAZ. (Fachinformation zu Atazanavir, Arzneimittelwechselwirkungen)

Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (Fachinformation zu Adalimumab, Arzneimittelwechselwirkungen)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (Fachinformation zu Adalimumab, Arzneimittelwechselwirkungen)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (Fachinformation zu Adalimumab, Arzneimittelwechselwirkungen)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (Fachinformation zu Adalimumab, Arzneimittelwechselwirkungen)

• Invasive fungal infections: For patients who develop a systemic illness on Adalimumab-fkjp, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic. (Fachinformation zu Adalimumab, Warnhinweise und Vorsichtsmaßnahmen)

Therapeutic drug monitoring is recommended with concomitant use Immunosuppressant /neoplastic: everolimus ↑ immunosuppressants Co-administration of everolimus and PREZCOBIX or PREZCOBIX PED is not recommended. irinotecan Discontinue PREZCOBIX or PREZCOBIX PED at least 1 week prior to starting irinotecan therapy. (Fachinformation zu Darunavir und Cobicistat, Arzneimittelwechselwirkungen)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (Fachinformation zu Denosumab, Warnhinweise und Vorsichtsmaßnahmen)

• Invasive fungal infections: For patients who develop a systemic illness on Adalimumab-fkjp, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic. (Fachinformation zu Adalimumab, Warnhinweise und Vorsichtsmaßnahmen)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus and others metabolized by CYP3A ↓ immunosuppressant Dose adjustments of the immunosuppressant may be required. (Fachinformation zu Efavirenz, Arzneimittelwechselwirkungen)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus, and others metabolized by CYP3A ↓ immunosuppressant Dose adjustments of the immunosuppressant may be required. (Fachinformation zu Efavirenz, Lamivudin und Tenofovir, Arzneimittelwechselwirkungen)

Immuno-suppressants: e.g., cyclosporine (CsA) sirolimus tacrolimus ↑ immuno-suppressants ↑ elvitegravir (with CsA) ↑ cobicistat (with CsA) Therapeutic monitoring of the immunosuppressive agents is recommended upon coadministration with GENVOYA. (Fachinformation zu Elvitegravir, Cobicistat, Emtricitabin und Tenofovir, Arzneimittelwechselwirkungen)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (Fachinformation zu Adalimumab, Arzneimittelwechselwirkungen)

Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (Fachinformation zu Etravirin, Arzneimittelwechselwirkungen)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (Fachinformation zu Adalimumab, Arzneimittelwechselwirkungen)

Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including fenofibrate, there is a risk that an interaction will lead to deterioration of renal… (Fachinformation zu Fenofibrat, Arzneimittelwechselwirkungen)

Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route… (Fachinformation zu Fenofibrinsäure, Arzneimittelwechselwirkungen)

• Invasive fungal infections: For patients who develop a systemic illness on Adalimumab-fkjp, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic. (Fachinformation zu Adalimumab, Warnhinweise und Vorsichtsmaßnahmen)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus ↑ Immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents. (Fachinformation zu Fosamprenavir, Arzneimittelwechselwirkungen)

• Invasive fungal infections: For patients who develop a systemic illness on Adalimumab-fkjp, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic. (Fachinformation zu Adalimumab, Warnhinweise und Vorsichtsmaßnahmen)

HBV reactivation has also been reported in patients receiving certain immunosuppressants or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (Fachinformation zu Ledipasvir und Sofosbuvir, Warnhinweise und Vorsichtsmaßnahmen)

Immunosuppressants: e.g. cyclosporine, tacrolimus, sirolimus ↑ immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with KALETRA. (Fachinformation zu Lopinavir und Ritonavir, Arzneimittelwechselwirkungen)

• Invasive fungal infections: For patients who develop a systemic illness on Adalimumab-fkjp, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic. (Fachinformation zu Adalimumab, Warnhinweise und Vorsichtsmaßnahmen)

Immunosuppressive Agents There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with nefazodone. (Fachinformation zu Nefazodon, Arzneimittelwechselwirkungen)

Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (Fachinformation zu Nevirapin, Arzneimittelwechselwirkungen)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Fachinformation zu Olmesartan, Amlodipin und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (Fachinformation zu Adalimumab, Arzneimittelwechselwirkungen)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (Fachinformation zu Penicillamin, Warnhinweise)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (Fachinformation zu Adalimumab, Arzneimittelwechselwirkungen)

• Invasive fungal infections: For patients who develop a systemic illness on Adalimumab-fkjp, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic. (Fachinformation zu Adalimumab, Warnhinweise und Vorsichtsmaßnahmen)

Glipizide Decrease exposure Immunosuppressive Agents Cyclosporine Decrease exposure Tacrolimus Prevention or Management: Monitoring of whole blood concentrations and appropriate dosage adjustments of tacrolimus are recommended when rifampin and tacrolimus are used concomitantly. (Fachinformation zu Rifampicin, Arzneimittelwechselwirkungen)

…Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine… (Fachinformation zu Rifapentin, Arzneimittelwechselwirkungen)

Immunosuppressants: cyclosporine, tacrolimus, sirolimus (rapamycin) ↑ immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with ritonavir. (Fachinformation zu Ritonavir, Arzneimittelwechselwirkungen)

HBV reactivation has also been reported in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (Fachinformation zu Sofosbuvir und Velpatasvir, Warnhinweise und Vorsichtsmaßnahmen)

In controlled trials of other TNF blockers in adult patients at higher risk for malignancies (i.e., patients with COPD with a significant smoking history and cyclophosphamide-treated patients with Wegener’s granulomatosis), a greater portion of malignancies occurred in the TNF blocker group compared to the control group. (Fachinformation zu Adalimumab, Warnhinweise und Vorsichtsmaßnahmen)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Fachinformation zu Telmisartan und Amlodipin, Arzneimittelwechselwirkungen)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Fachinformation zu Temsirolimus, Warnhinweise und Vorsichtsmaßnahmen)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (Fachinformation zu Adalimumab, Arzneimittelwechselwirkungen)

Cyclosporine, tacrolimus: Monitor for toxicities of these immunosuppressive drugs ( 7.1 ) (Fachinformation zu Tinidazol, Arzneimittelwechselwirkungen)

• Invasive fungal infections: For patients who develop a systemic illness on Adalimumab-fkjp, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic. (Fachinformation zu Adalimumab, Warnhinweise und Vorsichtsmaßnahmen)

Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (Fachinformation zu Adalimumab, Arzneimittelwechselwirkungen)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persists despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (Fachinformation zu Atorvastatin, Warnhinweise und Vorsichtsmaßnahmen)

Thirty-four patients were treated with corticosteroids and one patient was treated with a non-steroidal immunosuppressant. (Fachinformation zu Axitinib, Warnhinweise und Vorsichtsmaßnahmen)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (Fachinformation zu Ezetimib und Simvastatin, Warnhinweise und Vorsichtsmaßnahmen)

IMNM is characterized by proximal muscle weakness and elevated serum CK, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody, muscle biopsy showing necrotizing myopathy, and improvement with immunosuppressive agents. (Fachinformation zu Fluvastatin, Warnhinweise und Vorsichtsmaßnahmen)

IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (Fachinformation zu Lovastatin, Warnhinweise)

Immunosuppressive Drugs Tacrolimus: Tacrolimus has been shown to be metabolized via the CYP3A system. (Fachinformation zu Nifedipin, Vorsichtsmaßnahmen)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (Fachinformation zu Pitavastatin, Warnhinweise und Vorsichtsmaßnahmen)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (Fachinformation zu Pravastatin, Warnhinweise und Vorsichtsmaßnahmen)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (Fachinformation zu Propylthiouracil, Warnhinweise)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (Fachinformation zu Rosuvastatin, Warnhinweise und Vorsichtsmaßnahmen)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (Fachinformation zu Simvastatin, Warnhinweise und Vorsichtsmaßnahmen)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (Fachinformation zu Thiamazol, Warnhinweise)

…Repaglinide, Rosiglitazone: [See Warnings and Precautions ( 5.4 ) and Adverse Reactions ( 6.2 )] Insulin Insulin: [See Warnings and Precautions ( 5.4 ) and Adverse Reactions ( 6.2 )] Immunosuppressants: Cyclosporine Use With Caution Cyclosporine: There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with cyclosporine. (Fachinformation zu Clarithromycin, Arzneimittelwechselwirkungen)